Patch testing identified at least one relevant contact allergy in 41% of patients with hand eczema referred for evaluation, according to a report surfaced by AJMC. The figure comes from a referred cohort — patients whose hand eczema prompted clinician-directed patch testing — rather than from the general eczema population, a distinction that matters when interpreting how often contact allergy drives refractory or persistent disease.

Hand eczema is one of the most common dermatologic conditions seen in practice, and it frequently runs a chronic, relapsing course. Irritant exposure, atopic background and allergic contact dermatitis all overlap in these patients, which has long made the question of when to patch test a practical one for dermatologists. The 41% yield reported here supports a low threshold for referral: in a referred population, a substantial minority of patients carry an allergy that is directly relevant to their disease.

A relevant contact allergy, in this context, is one where the identified allergen plausibly explains or contributes to the patient's hand eczema — through occupational exposure, personal-care products, gloves, metals or other environmental contacts. Identifying such an allergen converts an inflammatory condition managed largely with topical anti-inflammatory therapy into one where allergen avoidance can change the disease course.

The finding also carries practice-level implications. Patients with hand eczema often cycle through topical corticosteroids, emollients and, in more severe cases, systemic immunosuppressants or biologic therapy. If more than four in ten referred patients have an allergen driving their disease, patch testing represents a diagnostic step that can redirect management away from escalating anti-inflammatory treatment and toward exposure reduction.

For clinicians, the data reinforce existing guidance that chronic, recurrent or treatment-resistant hand eczema warrants evaluation for allergic contact dermatitis. The referred-cohort design means the 41% figure should not be generalized to all patients with hand eczema, but it does quantify the diagnostic payoff of testing in the group clinicians select for evaluation.

How referral patterns and testing rates translate across different practice settings remains an open question, and one that future work will need to address as awareness of contact allergy's role in hand eczema grows.